Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Sponsor: M.D. Anderson Cancer Center
A PHASE2 clinical study on Hematopoietic and Lymphoid Cell Neoplasm and Influenza, this trial is actively recruiting participants. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 12 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .